An eLearning course for healthcare professionals, especially oncologists and oncology nurses. 

Immune checkpoint inhibitors help the immune system to destroy cancer cells. This type of immunotherapy works differently from chemotherapy and causes different kinds of side effects, called immune-related adverse events.

This course has a 2-year expiry date of  10th October 2025. If you complete this course after its expiry date, please double check all claims in this course with up-to-date, peer-reviewed information, as the diagnostic or treatment landscape may have changed. 

This course should take approximately 60 minutes to complete. 

CME/CPD Information

This course has been accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) with 1 European CME credit (ECMEC®).

This accreditation certifies the quality and relevance of the educational content.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

Expert Faculty

Bernardo L Rapoport MD
Specialist Physician and Medical Oncologist-in-Charge, The Medical Oncology Centre of Rosebank, Saxonwold, Johannesburg; and Department of Immunology, Faculty of Health Sciences, University of Pretoria, South Africa 

Helen Westman RN MN (Oncology)
Lung Cancer Nurse Coordinator, Cancer and Palliative Care Network; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia

An independent program provided as a service to medicine by MSD

MSD (Pty) Ltd (Reg. No. 1996/003791/07) 117-16th Road, Private Bag 3, Halfway House, 1685, South Africa. Tel: +27(0)11655-3000. www.msd.co.za. Copyright ©2021. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. ZA-KEY-00312. Exp. Date: 28/05/2023